DOCSLIB.ORG

Highlights in Metastatic Breast Cancer from the 2013 San Antonio Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Highlights in Metastatic Breast Cancer from the 2013 San Antonio Breast Cancer March 2014 Volume 12, Issue 3, Supplement 7 Highlights in Metastatic Breast Cancer From the 2013 San Antonio Breast Cancer Symposium (SABCS) A Review of Selected Presentations From the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 10-14, 2013 • San Antonio, Texas With expert commentary by: Joyce A. O’Shaughnessy, MD Chair, Breast Cancer Research Program Celebrating Women Chair in Breast Cancer Research Baylor-Sammons Cancer Center Texas Oncology US Oncology A CME Activity Dallas, Texas Approved for 1.75 AMA PRA Category 1 Credit(s) TM Sponsored by Postgraduate Institute for Medicine Release Date: March 2014 Expiration Date: March 31, 2015 Estimated time to complete activity: 1.75 hours Project ID: 9826 ON THE WEB: www.clinicaladvances.com Supported through an educational Indexed through the National Library of Medicine grant from Eisai Inc. (PubMed/Medline), PubMed Central (PMC), and EMBASE Target Audience Joyce A. O’Shaughnessy, MD—Consultant: Eisai, Genentech, Janssen Bio- This activity has been designed for all physicians, academicians, researchers, tech, GlaxoSmithKline, Lilly, sanofi, and Novartis. investigators, support staff, nurses, and program directors from the fields of oncology with a special interest in metastatic breast cancer. The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Statement of Need/Program Overview Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life part- Treatment of women with metastatic breast cancer lacks a single standard ner do not have any financial relationships or relationships to products or devices of care. Several novel agents have been approved in the past 5 years, and with any commercial interest related to the content of this activity of any amount others are undergoing evaluation in clinical trials. The management of during the past 12 months. Jacquelyn Matos: No real or apparent conflicts of symptoms in women with metastatic breast cancer can be complicated by interest to report. Kathy Boltz, PhD: No real or apparent conflicts of interest the additive effects of treatment toxicity. Personalized management, based to report. on factors such as hormone receptor and human epidermal growth fac- tor receptor 2 status, previous therapies, tumor burden, patient age, and Method of Participation comorbidities can improve outcomes. A large proportion of the abstracts There are no fees for participating in and receiving CME credit for this activ- presented at the 2013 San Antonio Breast Cancer Symposium focused ity. During the period March 2014 through March 31, 2015, participants on metastatic disease. Clinical trials of novel agents and regimens offered must 1) read the learning objectives and faculty disclosures; 2) study the both positive and negative data. Cellular studies provided insight into the educational activity; 3) complete the post-test by recording the best answer mechanism of the disease and identified potential avenues for treatment. to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key Educational Objectives to Postgraduate Institute for Medicine. You may also complete the post- After completing this activity, the participant should be better able to: test online at www.cmeuniversity com. On the navigation menu, click on • Evaluate efficacy and safety data for new and emerging agents for the treat- “Find Post-tests by Course” and search by project ID 9826. Upon success- ment of metastatic breast cancer fully completing the post-test and evaluation, your certificate will be made • Incorporate newly approved agents into treatment regimens to improve re- available immediately. sponse and survival outcomes of metastatic breast cancer patients • Implement individualized management plans based on factors such as hor- A statement of credit will be issued only upon receipt of a completed activity mone receptor and human epidermal growth factor receptor 2 status, previ- evaluation form and a completed post-test with a score of 70% or better. Your ous therapies, tumor burden, patient age, and comorbidities statement of credit will be mailed to you within three weeks. • Discuss future research directions and novel targets in the treatment of metastatic breast cancer Media Monograph Accreditation Statement This activity has been planned and implemented in accordance with the Es- Disclosure of Unlabeled Use sential Areas and policies of the Accreditation Council for Continuing Medical This educational activity may contain discussion of published and/or investi- Education (ACCME) through the joint sponsorship of Postgraduate Institute gational uses of agents that are not indicated by the FDA. PIM, Millennium for Medicine (PIM) and Millennium Medical Publishing, Inc. PIM is accred- Medical Publishing, Inc., and Eisai Inc., do not recommend the use of any ited by the ACCME to provide continuing medical education for physicians. agent outside of the labeled indications. Credit Designation The opinions expressed in the educational activity are those of the faculty The Postgraduate Institute for Medicine designates this enduring mate- TM and do not necessarily represent the views of PIM, Millennium Medical rial for a maximum of 1.75 AMA PRA Category 1 Credit(s) . Physicians Publishing, Inc., and Eisai Inc. Please refer to the official prescribing infor- should claim only the credit commensurate with the extent of their par- mation for each product for discussion of approved indications, contraindi- ticipation in the activity. cations, and warnings. Disclosure of Conflicts of Interest Disclaimer PIM assesses conflict of interest with its instructors, planners, managers, and Participants have an implied responsibility to use the newly acquired in- other individuals who are in a position to control the content of continuing formation to enhance patient outcomes and their own professional devel- medical education (CME) activities. All relevant conflicts of interest that are opment. The information presented in this activity is not meant to serve identified are thoroughly vetted by PIM for fair balance, scientific objectiv- as a guideline for patient management. Any procedures, medications, or ity of studies utilized in this activity, and patient care recommendations. other courses of diagnosis or treatment discussed or suggested in this activ- PIM is committed to providing its learners with high-quality CME activities ity should not be used by clinicians without evaluation of their patient’s and related materials that promote improvements or quality in healthcare conditions and possible contraindications or dangers in use, review of any and not a specific proprietary business interest or a commercial interest. applicable manufacturer’s product information, and comparison with rec- ommendations of other authorities. The contributing speakers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Disclaimer Funding for this presentations review has been provided through an educational grant from Eisai Inc. Support of this presentations review does not imply the supporter’s agreement with the views expressed herein. Every effort has been made to ensure that drug usage and other information are presented accurately; however, the ultimate responsibility rests with the prescribing physician. Millennium Medical Publishing, Inc., the supporter, and the participants shall not be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound at present under clinical investigation. ©2014 Millennium Medical Publishing, Inc., 611 Broadway, Suite 310, New York, NY 10012. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. HIGHLIGHTS IN METASTATIC BREAST CANCER FROM THE 2013 SABCS Highlights in Metastatic Breast Cancer From the 2013 San Antonio Breast Cancer Symposium (SABCS) P3-14-14 Neoadjuvant Phase II Trial With Hematologic adverse events (AEs) included leukope- Carboplatin and Eribulin in Triple Negative nia in 16 patients (6 with grade 3), neutropenia in 22 Breast Cancer Patients1 patients (12 with grade 3 and 5 with grade 4), anemia in 29 patients (6 with grade 3), and thrombocytopenia SB Giordano, JS Jeruss, KP Bethke, NM Hansen, in 24 patients (5 with grade 3 and 1 with grade 4.) S Khan, J Von Roenn, S Rosen, WL Gradishar, KP Nonhematologic AEs included fatigue, nausea, constipa- Siziopikou, C Meservey, V Kaklamani tion, elevated aspartate aminotransferase (AST), elevated A phase 2 neoadjuvant trial by Dr Sara Giordano and col- alanine aminotransferase (ALT), increased creatinine, and leagues enrolled 30 patients with biopsy-confirmed breast alopecia. The only grade 3 nonhematologic AE—elevated cancer at stages I through III who were negative for the ALT—occurred in 1 patient, and no grade 4 nonhemato- estrogen receptor (ER), the progesterone receptor, and the logic AEs were observed. human epidermal growth factor receptor 2 (HER2).1 These Cell culture studies indicated synergistic effects triple-negative patients received four 3-week cycles of carbo- from combining a cyclin-dependent kinase inhibitor
Load more

Recommended publications
  • Genome-Wide Association Study of Increasing Suicidal Ideation During Antidepressant Treatment in the GENDEP Project
    The Pharmacogenomics Journal (2012) 12, 68–77 & 2012 Macmillan Publishers Limited. All rights reserved 1470-269X/12 www.nature.com/tpj ORIGINAL ARTICLE Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project NPerroud1,2,3,RUher1, Suicidal thoughts during antidepressant treatment have been the focus of 1 2,3,4 several candidate gene association studies. The aim of the present genome- MYM Ng , M Guipponi , wide association study was to identify additional genetic variants involved in 5 6 JHauser, N Henigsberg , increasing suicidal ideation during escitalopram and nortriptyline treatment. WMaier7,OMors8, A total of 706 adult participants of European ancestry, treated for major M Gennarelli9, M Rietschel10, depression with escitalopram or nortriptyline over 12 weeks in the Genome- DSouery11, MZ Dernovsek12, Based Therapeutic Drugs for Depression (GENDEP) study were genotyped 13 14 with Illumina Human 610-Quad Beadchips (Illumina, San Diego, CA, USA). AS Stamp ,MLathrop , A total of 244 subjects experienced an increase in suicidal ideation AFarmer1, G Breen1,KJAitchison1, during follow-up. The genetic marker most significantly associated with CM Lewis1,IWCraig1 increasing suicidality (8.28 Â 10À7) was a single-nucleotide polymorphism and P McGuffin1 (SNP; rs11143230) located 30 kb downstream of a gene encoding guanine deaminase (GDA) on chromosome 9q21.13. Two suggestive drug-specific 1MRC Social, Genetic and Developmental Psychiatry associations within KCNIP4 (Kv channel-interacting protein 4; chromosome Centre, Institute of Psychiatry, King’s College 4p15.31) and near ELP3 (elongation protein 3 homolog; chromosome London, London, UK; 2Department of Psychiatry, 8p21.1) were found in subjects treated with escitalopram.
    [Show full text]
  • Supplemental Table 1. Complete Gene Lists and GO Terms from Figure 3C
    Supplemental Table 1. Complete gene lists and GO terms from Figure 3C. Path 1 Genes: RP11-34P13.15, RP4-758J18.10, VWA1, CHD5, AZIN2, FOXO6, RP11-403I13.8, ARHGAP30, RGS4, LRRN2, RASSF5, SERTAD4, GJC2, RHOU, REEP1, FOXI3, SH3RF3, COL4A4, ZDHHC23, FGFR3, PPP2R2C, CTD-2031P19.4, RNF182, GRM4, PRR15, DGKI, CHMP4C, CALB1, SPAG1, KLF4, ENG, RET, GDF10, ADAMTS14, SPOCK2, MBL1P, ADAM8, LRP4-AS1, CARNS1, DGAT2, CRYAB, AP000783.1, OPCML, PLEKHG6, GDF3, EMP1, RASSF9, FAM101A, STON2, GREM1, ACTC1, CORO2B, FURIN, WFIKKN1, BAIAP3, TMC5, HS3ST4, ZFHX3, NLRP1, RASD1, CACNG4, EMILIN2, L3MBTL4, KLHL14, HMSD, RP11-849I19.1, SALL3, GADD45B, KANK3, CTC- 526N19.1, ZNF888, MMP9, BMP7, PIK3IP1, MCHR1, SYTL5, CAMK2N1, PINK1, ID3, PTPRU, MANEAL, MCOLN3, LRRC8C, NTNG1, KCNC4, RP11, 430C7.5, C1orf95, ID2-AS1, ID2, GDF7, KCNG3, RGPD8, PSD4, CCDC74B, BMPR2, KAT2B, LINC00693, ZNF654, FILIP1L, SH3TC1, CPEB2, NPFFR2, TRPC3, RP11-752L20.3, FAM198B, TLL1, CDH9, PDZD2, CHSY3, GALNT10, FOXQ1, ATXN1, ID4, COL11A2, CNR1, GTF2IP4, FZD1, PAX5, RP11-35N6.1, UNC5B, NKX1-2, FAM196A, EBF3, PRRG4, LRP4, SYT7, PLBD1, GRASP, ALX1, HIP1R, LPAR6, SLITRK6, C16orf89, RP11-491F9.1, MMP2, B3GNT9, NXPH3, TNRC6C-AS1, LDLRAD4, NOL4, SMAD7, HCN2, PDE4A, KANK2, SAMD1, EXOC3L2, IL11, EMILIN3, KCNB1, DOK5, EEF1A2, A4GALT, ADGRG2, ELF4, ABCD1 Term Count % PValue Genes regulation of pathway-restricted GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, SMAD protein phosphorylation 9 6.34 1.31E-08 ENG pathway-restricted SMAD protein GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, phosphorylation
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Identification of Novel Genes in Human Airway Epithelial Cells Associated with Chronic Obstructive Pulmonary Disease (COPD) Usin
    www.nature.com/scientificreports OPEN Identifcation of Novel Genes in Human Airway Epithelial Cells associated with Chronic Obstructive Received: 6 July 2018 Accepted: 7 October 2018 Pulmonary Disease (COPD) using Published: xx xx xxxx Machine-Based Learning Algorithms Shayan Mostafaei1, Anoshirvan Kazemnejad1, Sadegh Azimzadeh Jamalkandi2, Soroush Amirhashchi 3, Seamas C. Donnelly4,5, Michelle E. Armstrong4 & Mohammad Doroudian4 The aim of this project was to identify candidate novel therapeutic targets to facilitate the treatment of COPD using machine-based learning (ML) algorithms and penalized regression models. In this study, 59 healthy smokers, 53 healthy non-smokers and 21 COPD smokers (9 GOLD stage I and 12 GOLD stage II) were included (n = 133). 20,097 probes were generated from a small airway epithelium (SAE) microarray dataset obtained from these subjects previously. Subsequently, the association between gene expression levels and smoking and COPD, respectively, was assessed using: AdaBoost Classifcation Trees, Decision Tree, Gradient Boosting Machines, Naive Bayes, Neural Network, Random Forest, Support Vector Machine and adaptive LASSO, Elastic-Net, and Ridge logistic regression analyses. Using this methodology, we identifed 44 candidate genes, 27 of these genes had been previously been reported as important factors in the pathogenesis of COPD or regulation of lung function. Here, we also identifed 17 genes, which have not been previously identifed to be associated with the pathogenesis of COPD or the regulation of lung function. The most signifcantly regulated of these genes included: PRKAR2B, GAD1, LINC00930 and SLITRK6. These novel genes may provide the basis for the future development of novel therapeutics in COPD and its associated morbidities.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Heterogeneity Between Primary Colon Carcinoma and Paired Lymphatic and Hepatic Metastases
    MOLECULAR MEDICINE REPORTS 6: 1057-1068, 2012 Heterogeneity between primary colon carcinoma and paired lymphatic and hepatic metastases HUANRONG LAN1, KETAO JIN2,3, BOJIAN XIE4, NA HAN5, BINBIN CUI2, FEILIN CAO2 and LISONG TENG3 Departments of 1Gynecology and Obstetrics, and 2Surgical Oncology, Taizhou Hospital, Wenzhou Medical College, Linhai, Zhejiang; 3Department of Surgical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang; 4Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang; 5Cancer Chemotherapy Center, Zhejiang Cancer Hospital, Zhejiang University of Chinese Medicine, Hangzhou, Zhejiang, P.R. China Received January 26, 2012; Accepted May 8, 2012 DOI: 10.3892/mmr.2012.1051 Abstract. Heterogeneity is one of the recognized characteris- Introduction tics of human tumors, and occurs on multiple levels in a wide range of tumors. A number of studies have focused on the Intratumor heterogeneity is one of the recognized charac- heterogeneity found in primary tumors and related metastases teristics of human tumors, which occurs on multiple levels, with the consideration that the evaluation of metastatic rather including genetic, protein and macroscopic, in a wide range than primary sites could be of clinical relevance. Numerous of tumors, including breast, colorectal cancer (CRC), non- studies have demonstrated particularly high rates of hetero- small cell lung cancer (NSCLC), prostate, ovarian, pancreatic, geneity between primary colorectal tumors and their paired gastric, brain and renal clear cell carcinoma (1). Over the past lymphatic and hepatic metastases. It has also been proposed decade, a number of studies have focused on the heterogeneity that the heterogeneity between primary colon carcinomas and found in primary tumors and related metastases with the their paired lymphatic and hepatic metastases may result in consideration that the evaluation of metastatic rather than different responses to anticancer therapies.
    [Show full text]
  • Targeting the DEK Oncogene in Head and Neck Squamous Cell Carcinoma: Functional and Transcriptional Consequences
    Targeting the DEK oncogene in head and neck squamous cell carcinoma: functional and transcriptional consequences A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements to the degree of Doctor of Philosophy (Ph.D.) in the Department of Cancer and Cell Biology of the College of Medicine March 2015 by Allie Kate Adams B.S. The Ohio State University, 2009 Dissertation Committee: Susanne I. Wells, Ph.D. (Chair) Keith A. Casper, M.D. Peter J. Stambrook, Ph.D. Ronald R. Waclaw, Ph.D. Susan E. Waltz, Ph.D. Kathryn A. Wikenheiser-Brokamp, M.D., Ph.D. Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide with over 50,000 new cases in the United States each year. For many years tobacco and alcohol use were the main etiological factors; however, it is now widely accepted that human papillomavirus (HPV) infection accounts for at least one-quarter of all HNSCCs. HPV+ and HPV- HNSCCs are studied as separate diseases as their prognosis, treatment, and molecular signatures are distinct. Five-year survival rates of HNSCC hover around 40-50%, and novel therapeutic targets and biomarkers are necessary to improve patient outcomes. Here, we investigate the DEK oncogene and its function in regulating HNSCC development and signaling. DEK is overexpressed in many cancer types, with roles in molecular processes such as transcription, DNA repair, and replication, as well as phenotypes such as apoptosis, senescence, and proliferation. DEK had never been previously studied in this tumor type; therefore, our studies began with clinical specimens to examine DEK expression patterns in primary HNSCC tissue.
    [Show full text]
  • Microarray Bioinformatics and Its Applications to Clinical Research
    Microarray Bioinformatics and Its Applications to Clinical Research A dissertation presented to the School of Electrical and Information Engineering of the University of Sydney in fulfillment of the requirements for the degree of Doctor of Philosophy i JLI ··_L - -> ...·. ...,. by Ilene Y. Chen Acknowledgment This thesis owes its existence to the mercy, support and inspiration of many people. In the first place, having suffering from adult-onset asthma, interstitial cystitis and cold agglutinin disease, I would like to express my deepest sense of appreciation and gratitude to Professors Hong Yan and David Levy for harbouring me these last three years and providing me a place at the University of Sydney to pursue a very meaningful course of research. I am also indebted to Dr. Craig Jin, who has been a source of enthusiasm and encouragement on my research over many years. In the second place, for contexts concerning biological and medical aspects covered in this thesis, I am very indebted to Dr. Ling-Hong Tseng, Dr. Shian-Sehn Shie, Dr. Wen-Hung Chung and Professor Chyi-Long Lee at Change Gung Memorial Hospital and University of Chang Gung School of Medicine (Taoyuan, Taiwan) as well as Professor Keith Lloyd at University of Alabama School of Medicine (AL, USA). All of them have contributed substantially to this work. In the third place, I would like to thank Mrs. Inge Rogers and Mr. William Ballinger for their helpful comments and suggestions for the writing of my papers and thesis. In the fourth place, I would like to thank my swim coach, Hirota Homma.
    [Show full text]
  • Schizophrenia-Associated Differential DNA Methylation in the Superior Temporal
    medRxiv preprint doi: https://doi.org/10.1101/2020.08.02.20166777; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Schizophrenia-associated differential DNA methylation in the superior temporal gyrus is distributed to many sites across the genome and annotated by the risk gene MAD1L1 Brandon C. McKinney1,, Christopher M. Hensler4, Yue Wei2, David A. Lewis1,4, Jiebiao Wang2, Ying Ding2, Robert A. Sweet1,3,4. University of Pittsburgh Departments of 1Psychiatry, 2Biostatistics, 3Neurology, and 4Translational Neuroscience Program, Pittsburgh, PA For questions and correspondence, please contact Brandon C. McKinney, MD, PhD. Mail: Biomedical Science Tower, Room W-1658 3811 O’Hara Street, Pittsburgh, PA 15213-2593 Express Mail: Biomedical Science Tower, Room W-1658 Lothrop and Terrace Streets, Pittsburgh, PA 15213-2593 Word Count Abstract: 246 Body: 3170 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.08.02.20166777; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . ABSTRACT: Background: Many genetic variants and multiple environmental factors increase risk for schizophrenia (SZ).
    [Show full text]
  • Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved In
    bioRxiv preprint doi: https://doi.org/10.1101/499616; this version posted December 19, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen Rany M. Salem1*, Jennifer N. Todd2, 3, 4*, Niina Sandholm5, 6, 7*, Joanne B. Cole2, 3, 4*, Wei-Min Chen8, Darrel Andrews9, Marcus G. Pezzolesi10, Paul M. McKeigue11, Linda T. Hiraki12, Chengxiang Qiu13, Viji Nair14, Chen Di Liao12, Jing Jing Cao12, Erkka Valo5, 6, 7, Suna Onengut- Gumuscu8, Adam M. Smiles15, Stuart J. McGurnaghan16, Jani K. Haukka5, 6, 7, Valma Harjutsalo5, 6, 7,17, Eoin P. Brennan9, Natalie van Zuydam18, 19, Emma Ahlqvist20, Ross Doyle9, Tarunveer S. Ahluwalia21, Maria Lajer21, Maria F. Hughes9, Jihwan Park13, Jan Skupien15, Athina Spiliopoulou11, Andrew Liu22, Rajasree Menon14, 23, Carine M. Boustany-Kari24, Hyun M. Kang23, 25, Robert G. Nelson26, Ronald Klein27, Barbara E. Klein27, Kristine E. Lee27, Xiaoyu Gao28, Michael Mauer29, Silvia Maeastroni30, Maria Luiza Caramori29, Ian H. de Boer31, Rachel G. Miller32, Jingchuan Guo32, Andrew P. Boright12, David Tregouet33, 34, Beata Gyorgy33, 34, Janet K. Snell-Bergeon35, David M. Maahs36, Shelley B. Bull37, Angelo J. Canty38, Colin N.A. Palmer39, Lars Stechemesser40, Bernhard Paulweber40, Raimund Weitgasser41, Jelizaveta Sokolovska42, 43, Vita Rovīte44, Valdis Pīrāgs42, 43, Edita Prakapiene45, Lina Radzeviciene46, Rasa Verkauskiene46, Nicolae Mircea Panduru6, 47, Leif C. Groop48, 49, Mark I. McCarthy18, 19, 50, Harvest F.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,906,283 B2 Mcmahon Et Al
    US007906283B2 (12) United States Patent (10) Patent No.: US 7,906,283 B2 McMahon et al. (45) Date of Patent: Mar. 15, 2011 (54) METHODS TO IDENTIFY PATIENTSAT RISK GeneCard for the PAPLN gene available via url: <genecards.org/cgi OF DEVELOPING ADVERSE EVENTS bin/carddisp.pl?gene=Papln&snp=299fisnp>, printed on Dec. 15, DURING TREATMENT WITH 2009.* ANTDEPRESSANT MEDICATION GeneCard for the IL28RA gene available via url: <genecards.org/ cgi-bin/carddisp.pl?gene=II28ra&snp=284iisnp>, printed on Dec. (75) Inventors: Francis J. McMahon, Bethesda, MD 15, 2009.* (US); Gonzalo E. Laje, Potomac, MD Thisted, R.A. May 25, 1998; available online via url: <statuchicago. (US); Silvia Paddock, Solna (SE): edu/~thisted, pp. 1-6.* Husseini K. Manji, Cabin John, MD Laje et al. American Journal of Human Genetics. 141B, Issue 7, pp. 724-725, abstract O22.3, available online Sep. 11, 2006.* (US); A. John Rush, Dallas, TX (US) Choi et al., Neuropsychobiology, 52, 155-162 (2005). (73) Assignees: The United States of America as Lipsky et al., Neuropsychopharmacology, 31(No. Suppl. I), S23-S24 represented by the Department of (2006). McMahon, American Journal of Medical Genetics, 141B(No. 7), Health and Human Services, 689-690 (2006). Washington, DC (US); Board of McMahon, Neuropsychopharmacology, 31(No. Suppl. I), S38-S39 Regents, the University of Texas (2006). System, Austin, IL (US) Murphy et al., American Journal Psychiatry, 160(10), 1830-1835 (2003). (*) Notice: Subject to any disclaimer, the term of this GenBank Accession No. AAH32004 (Jul 15, 2006). patent is extended or adjusted under 35 GenBank Accession No.
    [Show full text]
  • SUPPLEMENTARY APPENDIX an Extracellular Matrix Signature in Leukemia Precursor Cells and Acute Myeloid Leukemia
    SUPPLEMENTARY APPENDIX An extracellular matrix signature in leukemia precursor cells and acute myeloid leukemia Valerio Izzi, 1 Juho Lakkala, 1 Raman Devarajan, 1 Heli Ruotsalainen, 1 Eeva-Riitta Savolainen, 2,3 Pirjo Koistinen, 3 Ritva Heljasvaara 1,4 and Taina Pihlajaniemi 1 1Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Finland; 2Nordlab Oulu and Institute of Diagnostics, Department of Clinical Chemistry, Oulu University Hospital, Finland; 3Medical Research Center Oulu, Institute of Clinical Medicine, Oulu University Hospital, Finland and 4Centre for Cancer Biomarkers (CCBIO), Department of Biomedicine, University of Bergen, Norway Correspondence: [email protected] doi:10.3324/haematol.2017.167304 Izzi et al. Supplementary Information Supplementary information to this submission contain Supplementary Materials and Methods, four Supplementary Figures (Supplementary Fig S1-S4) and four Supplementary Tables (Supplementary Table S1-S4). Supplementary Materials and Methods Compilation of the ECM gene set We used gene ontology (GO) annotations from the gene ontology consortium (http://geneontology.org/) to define ECM genes. To this aim, we compiled an initial redundant set of 3170 genes by appending all the genes belonging to the following GO categories: GO:0005578 (proteinaceous extracellular matrix), GO:0044420 (extracellular matrix component), GO:0085029 (extracellular matrix assembly), GO:0030198 (extracellular matrix organization),
    [Show full text]